NNVC: NanoViricides Inc. Company Value to Net Income

NanoViricides Corp - graphic logo of issuer NNVC

NanoViricides, Inc. relies on partnerships with global virology centers to create nanopreparations against influenza and COVID-19. This price chart illustrates the dynamics of the asset, valued at -4.30, amid the implementation of software robots for clinical data analysis. The business is developing unique "traps" that mimic human cells, allowing for the neutralization of herpes and other viruses while preventing their mutation.

NNVC - NanoViricides P/E Multiple over the range 07/04/2022 - 11/12/2026

Analytical breakdowns for NanoViricides Inc. (NNVC)

- price and consensus price forecast:
Stock Price NanoViricides Corp|NNVC - Consensus Target
- market capitalization information:
Market Value NanoViricides, Inc.|NNVC - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Net Assets per Single Share NanoViricides|NNVC - Book Capitalization|Market Capitalization to Book Value nanoviricides.com|NNVC - Aggregate Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio NanoViricides, Inc.|NNVC - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital NanoViricides Corp|NNVC - Company Debts|Debts to Net Assets NanoViricides, Inc.|NNVC - Company Long-Term Debt|Company Short-Term Indebtedness NanoViricides|Quick Ratio nanoviricides.com
- earnings and market ratios statistics:
NNVC - Company Net Income|Net Profit Forecast NanoViricides, Inc.|NNVC - Price to Earnings Ratio|Projected Price to Earnings Ratio NanoViricides Corp|NNVC - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NanoViricides, Inc.|NNVC - Operating profit EBITDA|Net earnings per share for the last four quarters NanoViricides|NNVC - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months nanoviricides.com|NNVC - Earnings growth in current year|Consensus forecast of earnings per share growth for next year NanoViricides, Inc.
Comprehensive company analysis:NanoViricides, Inc.
Flagship merchandise of NanoViricides Inc.

The specifics of NanoViricides, Inc. (NNVC) biotechnological logistics require colossal expenditures for ultra-precise molecule transportation, which directly impacts net income. By analyzing the company's P/E ratio chart, an investor compares the market value of shares with actual earnings, identifying asset overvaluation or the risk of hidden losses through invested capital density and the gap between financial reports and market expectations.

Analysis of competing companies

P/E Multiple gilead.com|Price to Earnings Ratio CDTX (Cidara Corp)|NVAX (Novavax Inc) - Company Value to Net Income|CureVac Corp - Price to Earnings Ratio|Valneva Vaccines - Price to Earnings Ratio|Vir Biotechnology, Inc. - P/E Multiple|Business Payback Period siga.com SIGA|Emergent BioSolutions Inc. (EBS) - Price to Earnings Ratio|Atea Pharma - Company Value to Net Income|Price to Earnings Ratio IVVD|P/E Multiple Enanta Pharmaceuticals, Inc|Price to Earnings Ratio Inovio Pharmaceuticals (INO)|Business Payback Period hillevax.com|Price to Earnings Ratio Kalaris Therapeutics KLRS|DYAI: Price to Earnings Multiple|Talphera Corp - P/E Multiple|COCP - P/E Multiple|trawspharma.com (TRAW) - Price to Earnings Ratio|Price to Earnings Multiple DWTX|Price to Earnings Ratio Qualigen Therapeutics, Inc.|Market Cap to Earnings AlloVir Bio ALVR|Price to Earnings Ratio VBIV (VBI Vaccines Inc.)|Price to Earnings Ratio VIRI (virios.com)|P/E Multiple VXRT (Vaxart)